| Trial ID: | L3289 |
| Source ID: | NCT06694935
|
| Associated Drug: |
Qx1206
|
| Title: |
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus (T2DM)|Non-Alcoholic Fatty Liver Disease (NAFLD)
|
| Interventions: |
DRUG: QX1206
|
| Outcome Measures: |
Primary: Recommended Phase 2 Dose (RP2D), Baseline Day 1 up to Week 12 | Secondary: Hemoglobin A1c (HbA1c), Change in HbA1c percentage from baseline with QX1206, 12 Weeks|Fasting plasma glucose (FPG), Change in FPG mg/dL from baseline with QX1206, 12 Weeks|Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), Change in the HOMA-IR from baseline with QX1206, 12 Weeks|Fasting insulin, Change in fasting insulin pmol/L from baseline with QX1206, 12 Weeks
|
| Sponsor/Collaborators: |
Sponsor: 1Globe Health Institute
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2025-01-06
|
| Completion Date: |
2025-12
|
| Results First Posted: |
|
| Last Update Posted: |
2025-01-13
|
| Locations: |
Centricity Research Toronto LMC., Toronto, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT06694935
|
